Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160005 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, combination chemotherapy, drug screening /evaluation, human therapy evaluation, pharmacokinetics, pharmacology, clinical trial phase II /III /IV, comorbidity, cooperative study, drug interaction, drug metabolism, gender difference, intracellular, racial /ethnic difference, clinical research, female, human pregnant subject, human subject
Sponsored Links Excellgen http://Excellgen.com
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160001 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, human immunodeficiency virus 1, human therapy evaluation, biomarker, clinical trial phase II /III /IV, combination chemotherapy, cooperative study, cytokine, helper T lymphocyte, immunotherapy, interleukin 12, medical outreach /case finding, prognosis, reverse transcriptase inhibitor, therapy compliance, vertical transmission, viremia, zidovudine, blood cell count, clinical research, data collection, human subject, passive immunization
COMPLICATIONS OF HIV DISEASE AGENDA
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160002 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, HIV infection, communicable disease control, comorbidity, human therapy evaluation, medical complication, microorganism disease chemotherapy, opportunistic infection, secondary infection, AIDS therapy, antitubercular agent, biological response modifier, cachexia, candidiasis, clinical trial phase II /III /IV, cooperative study, cryptosporidiosis, cytomegalovirus, drug resistance, immunity, tuberculosis, viremia, clinical research, human subject, polymerase chain reaction
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160003 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS dementia complex, HIV infection, human therapy evaluation, nervous system disorder, nervous system disorder chemotherapy, neurologic manifestation, AIDS therapy, amitriptyline, clinical trial phase II /III /IV, combination chemotherapy, cooperative study, cytomegalovirus, foscarnet, ganciclovir, lidocaine, nervous system infection, neurotrophic factor, nimodipine, progressive multifocal leukoencephalopathy, zidovudine, biopsy, clinical research, human subject, neuropsychological test
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160004 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, human immunodeficiency virus 1, human therapy evaluation, immunomodulator, immunotherapy, pathologic process, AIDS related neoplasm /cancer, antineoplastic, biomarker, cellular immunity, clinical trial phase II /III /IV, communicable disease control, cooperative study, cytokine, humoral immunity, immunization, neoplasm /cancer immunotherapy, opportunistic infection, oxidative stress, viremia, virus replication, clinical research, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160006 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, human therapy evaluation, immunotherapy, reproductive system disorder, women s health, 2 3 dideoxyinosine, biomarker, candidiasis, cervix neoplasm, clinical trial phase I, clinical trial phase II /III /IV, comorbidity, cooperative study, drug screening /evaluation, human immunodeficiency virus 1, mucosal immunity, opportunistic infection, pharmacokinetics, clinical research, female, human pregnant subject, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160007 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, health care service evaluation, health science research analysis /evaluation, human therapy evaluation, outcomes research, prognosis, caregiver, clinical trial phase II /III /IV, cooperative study, data collection methodology /evaluation, health care cost /financing, health care service utilization, therapy compliance, behavioral /social science research tag, clinical research, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-160008 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, female, human therapy evaluation, medical outreach /case finding, women s health, African American, Hispanic American, Native American, clinical trial phase I, clinical trial phase II /III /IV, cooperative study, racial /ethnic difference, clinical research, human subject
CORE--ADVANCED TECHNOLOGY LABORATORIES
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-169001 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, biomedical facility, human therapy evaluation, immunology, pathologic process, pharmacology, antibody neutralization test, biomarker, clinical trial phase II /III /IV, cooperative study, cytokine, drug metabolism, human immunodeficiency virus 1, immunity, neutralizing antibody, pharmacokinetics, serology /serodiagnosis, virus antigen, clinical research, human subject, polymerase chain reaction
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150001 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, human immunodeficiency virus 1, human therapy evaluation, biomarker, clinical trial phase II /III /IV, combination chemotherapy, cooperative study, cytokine, helper T lymphocyte, immunotherapy, interleukin 12, medical outreach /case finding, prognosis, reverse transcriptase inhibitor, therapy compliance, vertical transmission, viremia, zidovudine, blood cell count, clinical research, data collection, human subject, passive immunization
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150003 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS dementia complex, HIV infection, human therapy evaluation, nervous system disorder, nervous system disorder chemotherapy, neurologic manifestation, AIDS therapy, amitriptyline, clinical trial phase II /III /IV, combination chemotherapy, cooperative study, cytomegalovirus, foscarnet, ganciclovir, lidocaine, nervous system infection, neurotrophic factor, nimodipine, progressive multifocal leukoencephalopathy, zidovudine, biopsy, clinical research, human subject, neuropsychological test
Sponsored Links Excellgen http://Excellgen.com
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150004 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, human immunodeficiency virus 1, human therapy evaluation, immunomodulator, immunotherapy, pathologic process, AIDS related neoplasm /cancer, antineoplastic, biomarker, cellular immunity, clinical trial phase II /III /IV, communicable disease control, cooperative study, cytokine, humoral immunity, immunization, neoplasm /cancer immunotherapy, opportunistic infection, oxidative stress, viremia, virus replication, clinical research, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150005 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, combination chemotherapy, drug screening /evaluation, human therapy evaluation, pharmacokinetics, pharmacology, clinical trial phase II /III /IV, comorbidity, cooperative study, drug interaction, drug metabolism, gender difference, intracellular, racial /ethnic difference, clinical research, female, human pregnant subject, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150006 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, human therapy evaluation, immunotherapy, reproductive system disorder, women s health, 2 3 dideoxyinosine, biomarker, candidiasis, cervix neoplasm, clinical trial phase I, clinical trial phase II /III /IV, comorbidity, cooperative study, drug screening /evaluation, human immunodeficiency virus 1, mucosal immunity, opportunistic infection, pharmacokinetics, clinical research, female, human pregnant subject, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150007 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, health care service evaluation, health science research analysis /evaluation, human therapy evaluation, outcomes research, prognosis, caregiver, clinical trial phase II /III /IV, cooperative study, data collection methodology /evaluation, health care cost /financing, health care service utilization, therapy compliance, behavioral /social science research tag, clinical research, human subject
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-150008 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, female, human therapy evaluation, medical outreach /case finding, women s health, African American, Hispanic American, Native American, clinical trial phase I, clinical trial phase II /III /IV, cooperative study, racial /ethnic difference, clinical research, human subject
CORE--ADVANCED TECHNOLOGY LABORATORIES
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5U01AI025868-159001 from National Institute Of Allergy And Infectious Diseases
Keywords: AIDS, AIDS therapy, HIV infection, antiAIDS agent, biomedical facility, human therapy evaluation, immunology, pathologic process, pharmacology, antibody neutralization test, biomarker, clinical trial phase II /III /IV, cooperative study, cytokine, drug metabolism, human immunodeficiency virus 1, immunity, neutralizing antibody, pharmacokinetics, serology /serodiagnosis, virus antigen, clinical research, human subject, polymerase chain reaction
Grants awarded to Charles Michael Van der horst
Charles Michael Van der horst
University Of North Carolina Chapel Hill, Office Of Sponsored Research, Chapel Hill, Nc 27599
Abstract: The long term goals of the Developmental Core are to solicit and provide funding for novel research projects of HIV research from our three member institutions (FHI, RTI, UNC) as well as our minority partners (within the UNC system, such as North Carolina Central University, Pembroke, UNC-Greensboro, etc., and outside, such as the University of Puerto Rico). We shall conduct objective peer review and assign senior investigators as mentors to nurture the research, publication and grant submission. In the first year of the new grant cycle we shall combine $150,000 of CFAR funds with $65,000 of UNC funds to support one to two year small ($5,000-$20,000) awards in all aspects of HIV research (basic and clinical sciences, translational research, epidemiology, vaccines, and behavioral research). We shall continue to focus on the ongoing epidemic in women, minorities, and international communities. In addition to our annual RFP, we shall set aside funds for directed research on emerging problems identified by Core Directors. Outreach and education will be accomplished through 1) presentation by Awardees at our weekly conference, 2) annual visits to HMUs on World AIDS Day with didactic talks for students and faculty and solicitation of collaborative research projects, 3) our annual HIV Update course for 400 clinicians from the Southeast, 4) our annual World AIDS Day Symposium at UNC for RTI, UNC and FHI, 5) our annual Community Forum reviewing new information for clients, and 6) a university-wide course on AIDS attended by 250 annually. Promising minority junior investigators will be identified and mentored until they have successful independent careers. Continuous quality improvement will remain a focus consisting of a review of the entire process including solicitation, review, mentoring and productivity of Awardees. The CFAR Developmental Core has awarded 85 small grants since its inception, of which 11 are still in progress or in data analysis. Developmental research has resulted in 55 outside grants, with six more currently in review; one patent; 64 papers, with 17 more either in press or under review; one free statistical package available on-line; and 71 presentations at national and international conferences. Developmental Awardees have already received a total of over $50,000,000 in subsequent funding
Keywords: AIDS; AIDS Virus; Acquired Immune Deficiency; Acquired Immune Deficiency Syndrome; Acquired Immune Deficiency Syndrome Virus; Acquired Immuno-Deficiency Syndrome; Acquired Immunodeficiency Syndrome; Acquired Immunodeficiency Syndrome Virus; Africa; Area; Award; Collaborations; Communities; Coordination and Collaboration; Country; Development; Disease; Disorder; Education; Educational aspects; Faculty; Fostering; Funding; HIV; HTLV-III; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Immunologic Deficiency Syndrome, Acquired; Institution; International; Investigators; LAV-HTLV-III; Link; Lymphadenopathy-Associated Virus; Mentors; Minority; North Carolina; Physicians; Population; Position; Positioning Attribute; Recruitment Activity; Research; Research Personnel; Research Resources; Researchers; Resources; Students; Virus-HIV; Woman; disease/disorder; forging; outreach; recruit; tool; working group
Budget start date: 1-JUN-2010
Budget end date: 31-MAY-2011
5P30AI050410-13_9001 (2010): $299643
5P30AI050410-12_9001 (2009): $293893
SOUTH AFRICA TUBERCULOSIS/AIDS TRAINING
Charles Michael Van der horst
University Of North Carolina Chapel Hill, Office Of Sponsored Research, Chapel Hill, Nc 27599
Grant 5U2RTW007373-04 from Fogarty International Center
Abstract: South Africa is one of the five countries worldwide that rank in the top ten of highest TB burden, highest TB/HIV burden and highest HIV burden. The lack of experienced investigators in clinical, operational and health services research s one of the main reasons behind the failure of South Africa to meet its tuberculosis control targets. This is a combined application from two prior planning grants from three South African universities (University of the Witwatersrand, University of Cape Town, Stellenbosch University) and two US universities (Johns Hopkins and University of North Carolina at Chapel Hill) to create a comprehensive TB training program. We shall teach short term courses in HIV, TB, research methods and research ethics in South Africa, identify talented South Africans for intermediate and long term training in South Africa and the US, mentor them throughout their training, fund them for preliminary research after completion of training and help them establish independent careers in South African. We have also established a link with the University of Malawi ICOHRTA to provide South to South training opportunities and the three other Fogarty grants Douglas Wassnaar-bioethics training at University of Pretoria; Mike Merson and Mary Crewe-HIV prevention training at University of Pretoria and Yale; Slim Karim at University of KwaZulu-Natal and Columbia. Specific aims 1 Train a cadre of senior faculty through 21 student years of MPH/PhD and 28 intermediate term experiences to carry out operations, health services and clinical research studying TB/HIV questions relevant to South Africa. 2.Train a cadre of junior faculty and staff, government and NGO staff through short term experiences in grants management, Good Clinical Practice, Human subjects protections, basic epidemiology and TB and HIV S.Train a team of at least 4 leaders from government, academia and NGOs to work in a cohesive manner through leadership training in the Public Health Leadership program at UNC 4.Create a sustainable TB training program in South Africa which does not require US investigator input 5.Strengthen the linkages of HIV/TB investigators throughout South Africa at University of the Witwatersrand, University of Cape Town, University of Pretoria, Stellenbosch University and University of KwaZulu-Natal through annual meetings focused on TB/HIV
Keywords: AIDS Virus; AIDS prevention; AIDS/HIV prevention; Academia; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; African; Bioethics; Clinical; Clinical Research; Clinical Study; Country; Doctor of Philosophy; Educational process of instructing; Epidemiology; Ethics, Biomedical; FLR; Faculty; Failure (biologic function); Funding; Good Clinical Practice; Government; Grant; HIV; HIV Prevention; HIV/AIDS prevention; HTLV-III; Health Care Research; Health Services; Health Services Evaluation; Health Services Research; Healthcare Research; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Investigators; LAV-HTLV-III; Leadership; Link; Lymphadenopathy-Associated Virus; Malawi; Medical Care Research; Mentors; Methodology, Research; North Carolina; Nyasaland; Operation; Operative Procedures; Operative Surgical Procedures; Ph.D.; PhD; Programs (PT); Programs [Publication Type]; Public Health; Republic of South Africa; Research; Research Ethics; Research Methodology; Research Methods; Research Personnel; Researchers; Short-Term Course; South Africa; Students; Surgical; Surgical Interventions; Surgical Procedure; Teaching; Training; Training Programs; Tuberculosis; Union of South Africa; Universities; Virus-HIV; Work; career; disseminated TB; disseminated tuberculosis; experience; experiment; experimental research; experimental study; failure; health care service; human subject protection; meetings; programs; public health medicine (field); research study; services research; surgery; tuberculous spondyloarthropathy
Project start date: 2007-07-01
Project end date: 2012-05-31
Budget start date: 1-JUN-2010
Budget end date: 31-MAY-2011
PFA/PA: RFA-TW-06-005
5U2RTW007373-04 (2010): $212156
5U2RTW007373-03 (2009): $209466
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 1U2RTW007373-01A1 from Fogarty International Center IRG: ZRG1
Abstract: South Africa is one of the five countries worldwide that rank in the top ten of highest TB burden, highest TB/HIV burden and highest HIV burden. The lack of experienced investigators in clinical, operational and health services research s one of the main reasons behind the failure of South Africa to meet its tuberculosis control targets. This is a combined application from two prior planning grants from three South African universities (University of the Witwatersrand, University of Cape Town, Stellenbosch University) and two US universities (Johns Hopkins and University of North Carolina at Chapel Hill) to create a comprehensive TB training program. We shall teach short term courses in HIV, TB, research methods and research ethics in South Africa, identify talented South Africans for intermediate and long term training in South Africa and the US, mentor them throughout their training, fund them for preliminary research after completion of training and help them establish independent careers in South African. We have also established a link with the University of Malawi ICOHRTA to provide South to South training opportunities and the three other Fogarty grants Douglas Wassnaar-bioethics training at University of Pretoria; Mike Merson and Mary Crewe-HIV prevention training at University of Pretoria and Yale; Slim Karim at University of KwaZulu-Natal and Columbia. Specific aims 1 Train a cadre of senior faculty through 21 student years of MPH/PhD and 28 intermediate term experiences to carry out operations, health services and clinical research studying TB/HIV questions relevant to South Africa. 2.Train a cadre of junior faculty and staff, government and NGO staff through short term experiences in grants management, Good Clinical Practice, Human subjects protections, basic epidemiology and TB and HIV S.Train a team of at least 4 leaders from government, academia and NGOs to work in a cohesive manner through leadership training in the Public Health Leadership program at UNC 4.Create a sustainable TB training program in South Africa which does not require US investigator input 5.Strengthen the linkages of HIV/TB investigators throughout South Africa at University of the Witwatersrand, University of Cape Town, University of Pretoria, Stellenbosch University and University of KwaZulu-Natal through annual meetings focused on TB/HIV.
Keywords: AIDS, Africa, training, university, African, Brazil, China, Internet, base, career, clinical research, clinical trial, communicable disease, ecosystem, epidemiology, ethics, experience, health, human subject, information system analysis, leadership, malaria, medicine, nurse, nursing, pharmacist, physician, prevention, public health, success, travel, tuberculosis, twin /multiplet
Project start date: 2007-07-01
Project end date: 2012-05-31
1U2RTW007373-01A1 (2007): $273518
Study Of Samples From HIV Subjects Changing Or Initiating Potent Therapy
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5M01RR000046-441233 from National Center For Research Resources IRG: RIRG
Keywords: AIDS therapy, HIV infection, human therapy evaluation, clinical research, human subject, patient oriented research
Project start date: 2003-12-01
Project end date: 2004-11-30
ACTG 384: PROTEASE INHIBITORS AND/OR TRANSCRIPTASE INHIBITORS IN INITIAL HIV INF
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5M01RR000046-441127 from National Center For Research Resources IRG: RIRG
Keywords: AIDS therapy, HIV infection, antiAIDS agent, drug screening /evaluation, human therapy evaluation, protease inhibitor, combination chemotherapy, human immunodeficiency virus 1, sulfonamide, viremia, clinical research, human subject, patient oriented research
Project start date: 2003-12-01
Project end date: 2004-11-30
ACTG 362: Efficacy Of Azithromycin Prophylaxis For The Primary Prevention Of MAC
Charles Michael Van der horst, Associate Professor
University Of North Carolina Chapel Hill Office Of Sponsored Research Chapel Hill, Nc 27599
Grant 5M01RR000046-441210 from National Center For Research Resources IRG: RIRG
Keywords: AIDS therapy, azithromycin, cardiovascular disorder prevention, chemoprevention, human therapy evaluation, blood lipid, cardiovascular disorder risk, memory, psychological concentration, clinical research, human subject, patient oriented research
Project start date: 2003-12-01
Project end date: 2004-11-30
Sponsored Links Excellgen http://Excellgen.com